# US 2003/0207941 A1 · Method of treating vascular endothelial growth factor mediated vascular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0207941 A1
- Document ID: US20030207941A1
- Status: Published application
- Kind: A1
- Application number: 10/417,466
- Filed: 2003-04-16
- Published: 2003-11-06
- Earliest claimed: 2002-05-03
- Inventors: David P. Bingaman; Michael A. Kapin; Daniel A. Gamache; Gustav Graff; John M. Yanni
- Web page: https://patentgrep.com/patent/US20030207941A1

## CPC

- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The use of amfenac and derivatives, including nepafenac, to treat vascular endothelial growth factor mediated vascular disorders.

## Claims

### Claim 1

A method for treating vascular endothelial growth factor mediated vascular disorders, which comprises, administering a pharmaceutically effective amount of amfenac.

### Claim 2 (depends on 1)

The method of claim 1 wherein the disorder is selected from the group consisting of exudative age related macular degeneration, proliferative diabetic retinopathy, retinal vein occlusion, proliferative vitreoretinopathy, neovascular glaucoma, corneal angiogenesis, retinal microvasculopathy, and retinal (macular) edema.

### Claim 3

A method for treating vascular endothelial growth factor mediated vascular disorders, which comprises, administering a pharmaceutically effective amount of nepafenac.

### Claim 4 (depends on 3)

The method of claim 3 wherein the disorder is selected from the group consisting of exudative age related macular degeneration, proliferative diabetic retinopathy, retinal vein occlusion, proliferative vitreoretinopathy, neovascular glaucoma, corneal angiogenesis, retinal microvasculopathy, and retinal (macular) edema.

### Claim 5 (depends on 1)

The method of claim 1 wherein the disorder is an ophthalmic disorder.

### Claim 6 (depends on 3)

The method of claim 3 wherein the disorder is an ophthalmic disorder.

### Claim 7 (depends on 2)

The method of claim 2 wherein the disorder is retinal (macular) edema.

### Claim 8 (depends on 4)

The method of claim 4 wherein the disorder is retinal (macular) edema.

### Claim 9 (depends on 2)

The method of claim 2 wherein the disorder is proliferative diabetic retinopathy.

### Claim 10 (depends on 4)

The method of claim 4 wherein the disorder is proliferative diabetic retinopathy.
